In their study, Paiva et al1 demonstrate that serial monitoring of measurable residual disease (MRD) during maintenance treatment of multiple myeloma (MM) can capture the dynamic conversion between negative (MRD-) and positive (MRD+) states, and can robustly predict progression-free survival (PFS). They also show the feasibility of longer-term MRD monitoring, providing a rationale for trials investigating intervention before frank relapse.
In this issue of Blood, Paiva et al1 report that serial monitoring of measurable residual disease (MRD) during maintenance treatment of multiple myeloma (MM) captures dynamic conversion between negative (MRD-) and positive (MRD+) states and robustly anticipates progression-free survival (PFS). They show the feasibility of longer-term MRD monitoring and provide a rationale for trials that investigate intervention before frank relapse.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据